Navigation Links
BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology

PRINCETON, N.J., March 3 /PRNewswire/ -- BioWa, Inc. announced today that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa's POTELLIGENT(R) Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).

"BioWa is pleased to extend this license with Genentech, which is a market leader in the field of antibody therapeutics," commented Dr. Masamichi Koike, President and CEO of BioWa. "We feel this alliance will strongly aid in the development of more effective targeted treatments for cancer and other diseases."

Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing POTELLIGENT(R) Technology for an additional number of targets. In return, BioWa will receive milestone payments and royalties on products developed by Genentech. Additional terms were not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd. (TSE: 4151), Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. In addition, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Both BioWa and Kyowa have POTELLIGENT(R) antibody products at various clinical stages. For more information about BioWa, visit its web site at

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.

SOURCE BioWa, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. DW Healthcare Partners Announces the Sale of Tandem Labs
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
5. Announces Distribution of Spectra Intelligence Research
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Wyeth Announces Executive Change in Finance Organization
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Pharmacopeia Announces Management Team Changes
11. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):